This is a mechanism module, not a specific disease. It models the conserved vascular-complication cascade that is downstream of, and shared by, every cause of chronic hyperglycemia; it deliberately does NOT model the type-specific routes into hyperglycemia (autoimmune beta-cell destruction, insulin resistance, undernutrition beta-cell impairment, monogenic beta-cell defects), which stay on the individual disease entries. Diabetes mellitus is represented in dismech as a Grouping over the distinct type entries (kb/groupings/Diabetes_Mellitus.yaml, owning MONDO:0005015) plus this shared mechanism module plus the per-type Disease entries; there is no blended umbrella pathophysiology graph. Disorder entries reference individual nodes via conforms_to (e.g., "diabetic_vascular_complications#Endothelial Dysfunction and Vascular Inflammation"). The key conformance target is the Endothelial Dysfunction and Vascular Inflammation central-effector node, the rate-limiting convergence point every hyperglycemic disorder funnels through. Conforming nodes in disorder files should include the corresponding cell types, biological processes, and causal edges, specialized to their disease context (e.g., a disease may elaborate the renal sub-cascade into glomerular, tubular, and fibrotic nodes, or the retinal/neural arms, beneath the module's collapsed Diabetic Microvascular and Macrovascular Injury effector). Worked conformers: Type I Diabetes, Type 2 Diabetes Mellitus, and Malnutrition-Related Diabetes Mellitus each declare a conforms_to edge onto the shared cascade. The drug-target design pattern: glucose-lowering and cardiorenal-protective therapy (here SGLT2 inhibitors) acts upstream on the Chronic Hyperglycemia trigger rather than on the downstream structural phenotype, reducing the whole complication cascade. Modules bind GO and CL terms only and do not use chemical (CHEBI) or disease (MONDO) term bindings; chemistry and disease concepts are described in prose, except in the treatments block where the therapeutic agent carries a CHEBI/NCIT identifier per the treatment schema.
Chronic Hyperglycemia
trigger
The shared, disorder-agnostic trigger. Sustained elevation of blood glucose — however it arises (absolute insulin deficiency, insulin resistance with beta-cell secretory failure, undernutrition-associated beta-cell impairment, or a monogenic beta-cell defect) — establishes the biochemical driver of long-term diabetic tissue injury. Because glucose enters insulin-independent vascular cells (endothelium, mesangium, Schwann cells, retinal pericytes) without downregulation, these cells experience the full intracellular glucose load and become the site of complication-initiating stress.
Downstream
-
Hyperglycemia-Induced Oxidative Stress and AGE-RAGE Activation
Chronic glucose excess increases reactive oxygen species and advanced glycation end-product formation, activating the canonical hyperglycemia-injury pathways.
Hyperglycemia-Induced Oxidative Stress and AGE-RAGE Activation
amplifier
The amplifying step. Hyperglycemia raises mitochondrial superoxide production, which activates the five interlocking pathways of diabetic complications: the polyol pathway, advanced glycation end-product (AGE) formation, increased AGE-receptor (RAGE) expression and ligand signaling, protein kinase C (PKC) isoform activation, and hexosamine-pathway overload. AGE-RAGE engagement propagates a self-amplifying pro-inflammatory, pro-oxidant signal. This oxidative and glycative stress is the biochemical amplifier that converts elevated glucose into vascular-wall injury.
Downstream
-
Endothelial Dysfunction and Vascular Inflammation
Oxidative and glycative stress impair endothelial homeostatic signaling and drive inflammatory activation of the vessel wall.
Endothelial Dysfunction and Vascular Inflammation
central effector
The rate-limiting central effector and key conformance target. Oxidative and AGE-RAGE stress disrupt the endothelium's balanced release of vasodilator (e.g., nitric oxide) and vasoconstrictor mediators, altering the physicochemical properties of the vascular wall. The endothelium shifts to a vasoconstricted, prothrombotic, pro-inflammatory phenotype with platelet hyperreactivity and leukocyte recruitment. This endothelial dysfunction with vascular inflammation is the pivotal, disorder-agnostic convergence point: every cause of chronic hyperglycemia funnels through it to reach both micro- and macrovascular injury. This is the key conformance target of the module.
Downstream
-
Diabetic Microvascular and Macrovascular Injury
Endothelial injury and vascular inflammation damage small vessels of the kidney, retina and nerve and accelerate atherosclerosis of the large arteries.
Diabetic Microvascular and Macrovascular Injury
effector
The effector step where endothelial dysfunction becomes structural vascular disease. In the microvasculature, injury of the small vessels of the kidney (glomerular and peritubular capillaries), retina, and peripheral nerve produces the classic diabetic microvascular triad. In the macrovasculature, endothelial dysfunction and inflammation accelerate atherosclerotic plaque formation in the coronary, cerebral, and peripheral arteries. A disease entry may elaborate this collapsed node into organ-specific sub-cascades (e.g., renal hemodynamic dysregulation -> glomerular injury -> tubular injury -> renal fibrosis) beneath this shared effector.
Downstream
-
Diabetic End-Organ Complications
Sustained micro- and macrovascular injury produces the clinical diabetic end-organ complications.
Diabetic End-Organ Complications
consequence
The clinical end state of the module. Chronic micro- and macrovascular injury manifests as diabetic kidney disease (albuminuria progressing to chronic kidney disease and end-stage renal failure), diabetic retinopathy (a leading cause of acquired blindness), diabetic neuropathy (peripheral and autonomic), and atherosclerotic cardiovascular disease (coronary artery disease, stroke, and peripheral artery disease). These complications are the principal source of diabetes-related morbidity and premature mortality and are the shared consequence of the conserved chronic-hyperglycemia -> oxidative/AGE-RAGE stress -> endothelial dysfunction -> vascular injury chain.